Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Cash flows from operating activities
Net loss			$ (70,513)	$ (159,307)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	$ 300	$ 300	941	1,005
Stock-based compensation			9,887	5,937
Research and development license expense				3,500
Change in fair value of warrant liability			67	100,456
Issuance costs for pre-funded warrant liability				2,567
Non-cash change in fair value of term loan			135
Impairment of long-lived assets	4,838	616	4,838	616
Non-cash lease expense			916	908
Other			678	581
Changes in operating assets and liabilities:
Prepaid expenses and other assets			(612)	4,008
Accounts payable			(1,416)	(1,065)
Accrued expenses and other liabilities			(1,527)	(4,260)
Deferred revenue			(6,311)	(11,847)
Net cash used in operating activities			(62,917)	(56,901)
Cash flows from investing activities
Purchase of research and development license				(3,500)
Purchase of property, plant and equipment			(376)	(3,852)
Other				10
Net cash used in investing activities			(376)	(7,342)
Cash flows from financing activities
Debt issuance costs for term loan			(18)
Proceeds from issuance of common stock and pre-funded warrants from underwritten public offering, net of underwriting discounts and sales commissions and other offering costs			77,140
Proceeds from issuance of common stock and pre-funded warrants from private placement, net of placement agent commissions and other offering costs				140,713
Proceeds from issuance of common stock from private placement				500
Payment of shelf registration costs				(387)
Proceeds from common stock issuances under ESPP			89	68
Other			(170)	(253)
Net cash provided by financing activities			77,041	140,641
Net increase in cash, cash equivalents and restricted cash			13,748	76,398
Cash, cash equivalents and restricted cash at the beginning of the period			146,540	90,517	$ 90,517
Cash, cash equivalents and restricted cash at the end of the period	160,288	166,915	160,288	166,915	146,540
Cash and cash equivalents	157,688	164,278	157,688	164,278	$ 143,940
Restricted cash	$ 2,600	$ 2,637	2,600	2,637
Supplemental disclosure of cash flow information:
Cash paid for interest			3,980	3,665
Supplemental disclosure of noncash investing and financing activities:
Issuance of warrants in connection with private placement				252
Property, plant and equipment in accounts payable and accrued expenses			133	45
Offering costs not yet paid			$ 360	$ 423